U.S. Assisted Reproductive Technology Market (By Type: In-Vitro Fertilization (IVF), Artificial Insemination; By End-use: Fertility Clinics & Other Facilities, Hospitals & Other Settings) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

U.S. Assisted Reproductive Technology Market Size and Growth

The U.S. assisted reproductive technology market size was valued at USD 5.78 billion in 2023 and is predicted to surpass around USD 9.54 billion by 2033 with a CAGR of 5.14% from 2024 to 2033.

Key Pointers

• By Type, the In-vitro Fertilization (IVF) sector held the largest revenue share of 92% in 2023.
• By Type, the artificial insemination is expected to expand at the highest CAGR from 2024 to 2033.
• By End-use, the fertility clinics and other facilities segment contributed the largest market share of 81% in 2023.

U.S. Assisted Reproductive Technology Market Overview

Assisted reproductive technology (ART) has revolutionized the landscape of fertility treatment in the United States. With advancements in medical science and technology, ART procedures offer hope to individuals and couples struggling with infertility.

U.S. Assisted Reproductive Technology Market Growth Factors

The growth of the U.S. assisted reproductive technology (ART) market growth is driven by an increasing infertility rate among couples, driven by factors such as lifestyle changes, delayed childbearing, and environmental influences, have bolstered demand for fertility treatments. Additionally, growing awareness and acceptance of ART procedures as viable options for overcoming infertility have contributed to market expansion. Moreover, advancements in medical technology and techniques, such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT), have significantly improved success rates, thus driving adoption and fueling market growth. Furthermore, supportive regulatory frameworks, coupled with insurance coverage for fertility treatments in some instances, have enhanced accessibility and affordability, further propelling the growth of the U.S. ART market.

U.S. Assisted Reproductive Technology Market Trends:

• Rising Demand: Increased infertility rates among couples due to factors like delayed childbearing, lifestyle changes, and environmental influences are driving demand for ART procedures.
• Insurance Coverage Expansion: Increasing insurance coverage for fertility treatments in some instances is making ART procedures more accessible and affordable to a broader range of patients.
• Shift Towards Elective Egg Freezing: The trend of elective egg freezing among women to preserve fertility options is gaining traction, driven by factors such as career advancement and delayed family planning.
• Rising Popularity of Single Parenthood: The acceptance and normalization of single parenthood, coupled with advancements in reproductive technology, are encouraging more individuals, including single women and LGBTQ+ individuals, to pursue ART treatments.
• Medical Tourism: The U.S. remains a preferred destination for international patients seeking high-quality ART services, contributing to the growth of medical tourism in the fertility sector.

U.S. Assisted Reproductive Technology Market Restraints:

• Cost Barriers: The high cost of ART procedures, including initial assessments, treatments, medications, and ancillary services, can pose a significant financial burden on patients, limiting accessibility for those with limited financial resources.
• Insurance Coverage Limitations: Despite increasing insurance coverage for fertility treatments, many plans have restrictions or limitations, such as age limits, diagnosis requirements, and treatment caps, which may impede access to ART services for certain individuals or couples.
• Ethical Concerns: Ethical considerations surrounding reproductive technologies, such as embryo disposition, selective reduction, and the commodification of human gametes and embryos, raise moral dilemmas and regulatory challenges that may constrain the expansion of the ART market.
• Regulatory Constraints: Stringent regulatory requirements, including FDA regulations on donor screening, laboratory standards, and reporting obligations, add complexity and compliance burdens to ART clinics, potentially limiting their ability to scale operations and innovate.
• Risk of Multiple Pregnancies: ART procedures, particularly IVF, carry a higher risk of multiple pregnancies, which can lead to complications for both mother and infants, including preterm birth, low birth weight, and neonatal intensive care requirements, posing clinical and financial challenges.

Type Insights

The In-vitro Fertilization (IVF) sector dominated the market with a significant revenue share of 92% in 2023. IVF is preferred over artificial insemination due to its higher success rates in treating infertility. Success rates in IVF procedures are influenced by the patient's age, with younger patients experiencing greater success compared to older individuals. The frozen non-donor procedure is typically chosen when the woman is producing healthy eggs but is undergoing ART due to male infertility or issues with fallopian tube function.

Artificial insemination is expected to experience the most rapid growth during the forecast period. This procedure is primarily recommended for minor fertility issues and is commonly sought after by same-sex couples or single women. Success rates in artificial insemination vary based on the patient's age. According to the Human Fertilization and Embryology Authority (HFEA), success rates per individual cycle of artificial insemination are approximately 15.8% for women under 35 years old, 11% for those aged 35 to 39, and 4.7% for women aged 40 to 42. Moreover, over 50% of women undergoing intrauterine insemination achieve pregnancy within the first 6 cycles.

End-use Insights

The fertility clinics and other facilities segment emerged as the market leader in 2023, capturing a substantial 81% share of the total revenue. This segment is expected to maintain its dominant position and exhibit the fastest growth rate throughout the forecast period. The significant market share and rapid expansion can be attributed to the increasing prevalence of infertility cases, necessitating specialized facilities for assisted reproductive procedures.

Fertility clinics are preferred by physicians and surgeons as they offer specialized expertise and are equipped to handle complex fertility conditions. These clinics are the primary setting for invasive procedures such as intrauterine insemination and intratubal insemination. Factors such as cost-effectiveness, specialization, expertise, and personalized treatment options are anticipated to drive further growth in this segment over the forecast period.

U.S. Assisted Reproductive Technology Market Key Companies

• Cosmos Biomedical Ltd.
• Microm U.K. Ltd.
• CooperSurgical Inc.
• FUJIFILM Irvine Scientific
• Cryolab Ltd.
• Vitrolife AB
• European Sperm Bank
• Bloom IVF Centre
• Merck KGaA
• Ferring B.V.

Recent Developments

• In August 2023, Reproductive Medicine Associates (RMA) acquired Conceptions Reproductive Associates of Colorado, adding Colorado to its network of 25 fertility centers located across New Jersey, Texas, Florida, California, Pennsylvania, and Washington.
• In March 2022, FUJIFILM Irvine Scientific completed the acquisition of Shenandoah Biotechnology, a major manufacturer of recombinant proteins. The terms of the deal were not disclosed.
• In January 2022, Future Fertility secured over USD 6 million in Series A funding to expedite the expansion of its artificial intelligence-based IVF products. While many companies in the fertility sector have concentrated on embryos, Future Fertility distinguishes itself as the first company to offer noninvasive egg testing to patients through fertility clinics.
• In July 2021, Hamilton Throne Ltd., a global provider of ART research, acquired IVFTECH ApS (IVFtech) and its affiliated firm, K4 Technology ApS. IVFtech specializes in providing laminar flow workstations and high-capacity incubators for ART procedures with the assistance of its affiliated firm, K4. The transaction was valued at USD 8 million.

U.S. Assisted Reproductive Technology Market Segmentation:

By Type

• In-vitro Fertilization (IVF)
  • Fresh Donor
  • Frozen Donor
  • Fresh Non-donor
  • Frozen Non-donor
• Artificial Insemination
  • Intrauterine Insemination
  • Intracervical Insemination
  • Intravaginal Insemination
  • Intratubal Insemination

By End-use

• Fertility Clinics & Other Facilities
• Hospitals & Other Settings